注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Amarin Corporation PLC是一家製藥公司。該公司專注於改善心血管(CV)、健康和降低CV風險的療法的商業化和開發。該公司通過VASCEPA的開發和商業化運營。其主導產品Vasicpa(icosapent ethyl)膠囊被用作飲食的輔助藥物,以降低患有嚴重高甘油三酯血症的成年患者的甘油三酯水平。Vascepa的這一適應症被稱為MARINE適應症,主要基於Vascepa在該獲批患者群體中的MARINE研究結果。該公司主要將Vascepa銷售給批發商以及選定的區域批發商和專業藥房供應商,或統稱為其分銷商,後者又將Vascepa轉售給零售藥店,再轉售給患者和醫療保健提供者。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Odysseas D. Kostas | 48 | 2023 | Independent Non-Executive Chairperson of the Board |
John Climax | 70 | 2006 | Chairman of Scientific Advisory Board |
Mark W. Pierce | - | 2006 | Member of the Scientific Advisory Board |
Reid Patterson | - | 2006 | Member of the Scientific Advisory Board |
Jan D. Wallace | 82 | 2006 | Member of Scientific Advisory Board |
Mark Anthony DiPaolo | 51 | 2023 | Independent Non-Executive Director |
Patrice Eadon Bonfiglio | 40 | 2023 | Independent Non-Executive Director |
Diane E. Sullivan | 60 | 2023 | Independent Non-Executive Director |
Oliver O'Connor | 61 | 2023 | Independent Non-Executive Director |
Paul Cohen | 48 | 2023 | Independent Non-Executive Director |
Louis E. Sterling | 43 | 2023 | Independent Non-Executive Director |
Keith L. Horn | 64 | 2023 | Independent Non-Executive Director |
Patrick Holt | - | 2023 | President, CEO & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核